One organization submitted a request for access to information, addressed to the Ministry of Health, Consumption and Social Welfare to get to know the PVL of Kymriah, the first therapy to treat acute lymphoblastic leukemia of refractory B cells and for the indication of diffuse B lymphoma of large cell. The specific objective criteria under which this therapy is approved, as well as its economic conditions.
The Ministry provided information but the applicant considered it partial.
When the complaint was filed, the Council of Transparency and Good Governance considered it, since the Ministry’s response is too generic. It is precisely the parameters of selective funding and therapeutic utility that must have guided the Inter-Ministerial Commission on Drug Prices to make the decision to include the drug Kymriah in public funding, and it is for these reasons that the claimant wishes to know.
